ClinicalTrials.gg
RecruitingNCT07419438SUPREEMIEUpdated Nov 10, 2026

Supraglottic Airway for Resuscitation in Preemies

An interventional study of Supraglottic Airway in Respiratory Failure, Premature Neonates and Delivery Room Resuscitation, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 0 Days to 1 Day. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
0 Days to 1 Day
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.

Planned enrollment
173rd of 253
20 · median 42
Started
2026
with 17 others
No phase
159 of 349
30 open now
Primary completion
2027-02
later than 30 of 59 live
Registered
336th of 349
by date

Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 173rd largest by planned enrollment of the 253 interventional ones that give a count, is one of 18 that started in 2026, is one of 159 with no phase, reaches primary completion later than 30 of the 59 other live ones, and was the 336th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 0 Days to 1 Day · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Respiratory Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The goal of this single-arm intervention trial is to learn whether using a supraglottic airway (SA) as the primary interface for positive pressure ventilation (PPV) is feasible during delivery room resuscitation of premature infants. This study will be conducted in premature infants born between 29 0/7 and 33 6/7 weeks' gestation who require PPV at birth.

The main question it aims to answer is: Is it feasible to use a supraglottic airway as the primary interface to provide effective PPV during delivery room resuscitation in 29 0/7 to 33 6/7 weeks' gestation premature infants?

Participants will (1)Be screened prenatally and have informed consent obtained from the birth parent prior to delivery; (2)Be rescreened for eligibility on the day of delivery before receiving the study intervention; (3)Receive PPV using a supraglottic airway as the primary ventilation interface if resuscitation is required at birth; and (4)Have clinical and procedural data collected during delivery room resuscitation and for up to 24 hours after birth.

03

Conditions studied

  • Respiratory Failure
  • Premature Neonates
  • Delivery Room Resuscitation
  • Positive Pressure Ventilation
  • Neonatal Resuscitation
  • Supraglottic Airway
  • Laryngeal Mask
  • Laryngeal Mask Airways

Keywords

  • Respiratory failure
  • Premature neonates
  • Delivery Room Resuscitation
  • Positive pressure ventilation
  • Neonatal resuscitation
  • Supraglottic Airway
  • laryngeal mask
  • Laryngeal Mask Airways
04

Who can participate

Ages eligible
0 Days to 1 Day
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age 29 0/7 to 33 6/7 weeks at birth
  • Estimated fetal weight >/= 1000 grams at birth
  • Clinical decision to initiate PPV
  • Parental

Exclusion criteria

Exclusion Criteria:

  • Major anomalies or aneuploidy
  • Palliative care planned or considered
  • Not resuscitated in the infant resuscitation room
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Supraglottic Airway

    Premature infants who require positive pressure ventilation immediately after birth will receive ventilation through a supraglottic airway used as the primary airway interface during delivery room resuscitation.

    Other: Supraglottic Airway

Interventions

  • OtherSupraglottic Airway

    Use of a supraglottic airway as the primary interface for delivery of positive pressure ventilation during neonatal resuscitation.

06

What researchers measure

Primary outcomes

  1. Feasibility of Supraglottic Airway as Primary Ventilation Interface

    Feasibility defined as successful use of a supraglottic airway as the primary interface to deliver positive pressure ventilation for up to 10 minutes of life or until discontinuation of positive pressure ventilation, without need for immediate escalation to an alternative airway interface.

    Time frame: Immediately after birth (up to 10 minutes of life)

Secondary outcomes

  1. Time to Supraglottic Airway Placement During Resuscitation

    Time in minutes from birth to placement of the supraglottic airway as the primary interface for delivery of positive pressure ventilation during delivery room resuscitation.

    Time frame: Immediately after birth

  2. Duration of Supraglottic Airway Use During Resuscitation

    Total duration in minutes that the supraglottic airway is used as the primary interface to deliver positive pressure ventilation during delivery room resuscitation.

    Time frame: Immediately after birth

Other outcomes

  1. Heart Rate During Resuscitation and First 24 Hours of Life

    Heart rate measured in beats per minute (bpm) using continuous cardiorespiratory monitoring during neonatal resuscitation and within the first 24 hours after birth.

    Time frame: Birth to 24 hours of life

  2. Oxygen Saturation During Resuscitation and First 24 Hours of Life

    Peripheral oxygen saturation (SpO₂), measured as a percentage using pulse oximetry during neonatal resuscitation and within the first 24 hours after birth.

    Time frame: Birth to 24 hours of life

  3. Need for Advanced Cardiorespiratory Interventions Within 24 Hours of Birth

    Occurrence of cardiorespiratory interventions including endotracheal intubation, chest compressions, administration of epinephrine, or initiation of mechanical ventilation during resuscitation or within the first 24 hours after birth, recorded as yes/no.

    Time frame: Birth to 24 hours of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 11 months is below that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Feb 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Feb 19, 2026
StartActual
Mar 13, 2026
Primary completionEst.
Feb 2027was Oct 2026
CompletionEst.
Feb 2027was Oct 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Feb 2027
Nov 10, 2026
Study completion
Oct 2026→Feb 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Oct 2026→Feb 2027
    Study completion Oct 2026→Feb 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07419438
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Mar 13, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

Sura Lee
Contact
sura.lee@pennmedicine.upenn.edu
215-873-9339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion